The recent surge in funding into niche pharmaceutical companies, particularly those focusing on experimental therapies and difficult drug development programs, has fueled what some are calling "High Roller Pharma." https://dianegjrf161113.webbuzzfeed.com/40483243/elite-stakeholder-pharma-risky-bet